Heartflow vs. Iovance Biotherapeutics: A Comprehensive Comparison

Healthcare is undergoing a significant transformation with the integration of Artificial Intelligence (AI) and personalized cell therapy. Two high-growth innovators, Heartflow Inc. (NASDAQ: HTFL) and Iovance Biotherapeutics (NASDAQ: IOVA), are at the forefront of this revolution. Both companies are scaling commercial operations in high-stakes medical fields, offering investors exposure to cutting-edge clinical technology.

Source: media.zenfs.com

Heartflow focuses on non-invasive AI diagnostics for heart disease, while Iovance develops personalized cell therapies to treat solid tumors. In this article, we will evaluate their financial health and market risks to determine which aligns best with your investment strategy.

The Case for Heartflow Inc.

Heartflow sells AI-enabled software designed to analyze coronary artery disease. The company provides these tools to clinicians to help identify blockages more accurately than traditional tests. Heartflow currently maintains about 1,465 accounts in the U.S. and is expanding its reach among healthcare stocks by focusing on its core FFR CT Analysis product, which generates nearly 98% of its revenue.

In FY 2025, revenue reached about $176 million, a 40% increase over the prior year. Despite this strong top-line expansion, the business reported a net loss of $116.8 million for the period. As of its December 2025 balance sheet, the debt-to-equity ratio is approximately 0.1x, indicating a low level of borrowing relative to shareholders’ equity. Free cash flow, calculated as cash from operations minus capital expenditures, was nearly negative $59.0 million for the year.

The Case for Iovance Biotherapeutics

Iovance Biotherapeutics develops personalized tumor-infiltrating lymphocyte therapies to treat patients with cancer. The company generates revenue by selling its primary products, Amtagvi and Proleukin, to hospitals, clinics, and specialized distributors. To support its pipeline, Iovance maintains critical license agreements with major organizations, including Novartis AG (NYSE: NVS) and Cellectis SA (NASDAQ: CLLS), while operating its own centralized manufacturing facility.

During FY 2025, the company reported revenue of $263.5 million, reflecting a significant 60.6% growth rate over the prior year. This increase followed the successful commercial scaling of its lead therapies across North American markets. However, the company recorded a net loss of roughly $391 million, slightly deeper than 2024. According to its December 2025 balance sheet, Iovance maintains a debt-to-equity ratio of approximately 0.1x. Free cash flow for fiscal year 2025 was negative $336.2 million, reflecting the heavy capital requirements of personalized cell therapy manufacturing and clinical trials.

Risk Profile Comparison

Heartflow relies on a single product for 98% of its revenue, creating significant concentration risk. The company is also cooperating with a U.S. Department of Justice investigation regarding its marketing activities and financial arrangements with providers. Furthermore, the proposed 2026 Medicare rules suggest a 15% reduction in reimbursement for its core service, while competition remains intense from GE HealthCare Technologies Inc (NASDAQ: GEHC), Siemens, and Philips (NYSE: PHG).

Iovance faces substantial financial risk with an accumulated deficit of $2.9 billion as of March 31, 2026. The manufacturing process for its therapies is highly complex and patient-specific, which poses risks of contamination or supply chain failure. Additionally, the company is managing the aftermath of a 19% workforce reduction intended to extend its cash runway, which may impact its long-term operational capacity and growth initiatives.

Valuation Comparison

Neither company is seen making a profit in 2026, so neither has a forward price-to-earnings ratio. Heartflow Inc. Common Stock has a sector benchmark of 30.09, while Iovance Biotherapeutics has a sector benchmark of 24.44. The forward P/E ratio for Heartflow Inc. Common Stock is 35.56, and for Iovance Biotherapeutics, it is 29.24.

Despite the challenges, Iovance Biotherapeutics gets the nod over Heartflow by virtue of its lower price-to-sales ratio under the guide of buying good companies at good prices.

Each business is exciting in its own way, but investors must carefully weigh the risks and rewards before making an informed decision.